Corrections:

Carminia Maria Della Corte¹, Umberto Malapelle², Elena Vigliar², Francesco Pepe², Giancarlo Troncone², Vincenza Ciaramella¹, Teresa Troiani¹, Erika Martinelli¹, Valentina Belli¹, Fortunato Ciardiello¹ and Floriana Morgillo¹

¹Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale “F. Magrassi e A. Lanzara,” Università degli studi della Campania “Luigi Vanvitelli”, Naples, Italy
²Dipartimento di Sanità Pubblica, Università degli Studi di Napoli Federico II, Naples, Italy

Published: December 29, 2022

Copyright: © 2022 Corte et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 5A, the ‘α-tubulin’ panel is an accidental duplicate of the ‘Akt’ panel. In addition, the ‘GLI-1’ panel has been replaced with a parallel WB evaluating GLI-1 where HCC827 shows the presence of a low level of GLI-1, thus showing 7 lanes instead of 6. The corrected Figure 5A, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2019; 10:23020–23032. DOI: https://doi.org/10.18632/oncotarget.15479

Figure 5: Western blot analysis on protein lysates and experiments on cell lines established in vitro from EGFR inhibitors-resistant HCC827 human tumor xenografts. (A) Western blot analysis on protein lysates from representative tumors of each line of treatment of EGFR-TKIs: gefitinib, afatinib, osimertinib.